Although doxorubicin has become a key drug in cancer treatment, the resistance of colorectal carcinoma to doxorubicin is a major problem in clinical practice. F-box and WD repeat domaincontaining 7 (FBXW7) plays important roles in human cancers and is one of the major causes of drug resistance. The miR-223/FBXW7 pathway has been reported to be a crucial clue to the mechanism of chemoresistance in many human cancers, such as gastric cancer, breast cancer, and nonsmall cell lung cancer. However, it is unclear whether similar mechanisms of doxorubicin resistance are involved in colorectal cancer (CRC). The aim of the current study was to evaluate the role of miR-223/FBXW7 pathway in chemosensitivity in different CRC cell lines and to investigate the relevant underlying mechanisms. We found that high levels of FBXW7 expression were associated with increased doxorubicin sensitivity in different CRC cell lines, and FBXW7 was regulated by miR-223. Overexpression of miR-223 decreased FBXW7 expression and the sensitivity of CRC cells to doxorubicin, while suppression of miR-223 had the opposite effect. Moreover, epithelial-mesenchymal transition (EMT) was proved to be regulated by miR-223/FBXW7 pathway and involved in the drug resistance. In conclusion, miR-223/FBXW7 axis regulates doxorubicin sensitivity through EMT in CRC, which may lead to the development of individualized treatment in clinical practice.
Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second cause of cancer-related death in the world [1, 2] . Despite the recent progress in cancer diagnosis and treatment, the prognosis of patients with CRC remains poor. Although combination of chemotherapy is an important treatment method for CRC patients, the development of drug resistance is still the most significant obstacle to effective chemotherapy [3] . Therefore, it is urgent to elucidate the molecular mechanisms underlying the drug resistance in CRC.
F-box and WD repeat domain-containing 7 (FBXW7) is the substrate recognition component of an evolutionarily conserved SCF (complex of SKP1, CUL1, and F-box protein)-type ubiquitin ligase complex. FBXW7 is a tumor suppressor which regulates a network of proteins with central roles in cell division, cell growth, and differentiation [4, 5] . It has been suggested that altered FBXW7 expression is one of the major causes of carcinogenesis, cancer development, and chemoresistance [6] .
MicroRNAs (miRNAs) are a class of short, non-coding RNA molecules and regulate many genes through sequence-specific binding to their target mRNAs, leading to the mRNA degradation or translation repression. MiRNAs are involved in various biological processes, such as cell death, cell proliferation, and drug resistance [7, 8] . Most recently, several studies have revealed a correlation between miR-223 expression and FBXW7 expression, and the miR-223/ FBXW7 pathway regulated sensitivity to various chemotherapeutic reagents, such as doxorubicin, paclitaxel, and cisplatin in gastric cancer, breast cancer, hepatocellular carcinoma, and non-small cell lung cancer [9] [10] [11] [12] . However, it is unclear whether similar mechanisms of doxorubicin resistance are involved in CRC.
It is important to clarify the mechanisms responsible for sensitivity to doxorubicin in CRC, which will be helpful for the development of new therapeutic strategies. In the present study, we aimed to investigate the miR-223/FBXW7 axis in regulation of the sensitivity of CRC cells to doxorubicin and the relevant underlying mechanisms.
Materials and Methods

Clinical samples
All CRC specimens were obtained from patients who underwent urgical resection. Informed consent was obtained before the surgeries were performed at Xianning Central Hospital, the First Affiliated Hospital of Hubei University of Science and Technology (Xianning, China). Fifty paired CRC tissues and adjacent normal tissues were collected from each patient and validated by pathological examination ( Table 1 ). All patients were diagnosed by pathological analyses based on the International Union Against Cancer (UICC) defined TNM criteria. The use of human specimens and all of the experimental procedures in this study were approved by the ethics committee of Xianning Central Hospital.
Cell culture and transfection
Human CRC cell lines (HT-29, SW480, SW620, and LoVo) were obtained from the American Type Culture Collection (ATCC, Manassas, USA) and maintained according to ATCC guidelines. HT-29 cells were cultured in minimum essential medium (Gibco, Carlsbad, USA), SW480
and SW620 cells were in Dulbecco's modified Eagle's medium (Gibco), and LoVo cells were in RPMI 1640 medium (Gibco). All the cells were cultured at 37°C with 5% CO 2 in medium containing 10% FBS supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco). Doxorubicin was purchased from Sigma (St Louis, USA).
Cytotoxicity assay
A Cell Counting Kit-8 Kit (CCK-8; Dojindo, Kumamoto, Japan) was used to evaluate the relative cell viability. In brief, four human CRC cell lines (HT-29, SW480, SW620, and LoVo) were seeded into a 96-well microplate (5 × 10 3 cells/well) and incubated overnight until they were adherent. After 24 h of culture in a serum-free medium, CRC cells were treated with doxorubicin at different concentrations (0.2, 0.4, 0.6, 1.0, and 1.5 μM) for 72 h. Then, cells were washed twice in phosphate-buffered saline (PBS) and then 10 μl of CCK-8 solution was added into the medium and incubated for another 2 h. The absorbance of the medium was measured at 450 nm using an MRX II microplate reader (Dynex, Chantilly, USA).
Western blot analysis
Cells were harvested and washed twice in PBS. Then the cells were lysed in equal volumes of ice cold lysis buffer and a protease inhibitor cocktail. 
RNA extraction and quantitative real-time PCR
Total RNA was extracted from cells or tissues using TRIzol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The concentration and quality of the total RNA were assessed with Nanodrop Spectrophotometer (Thermo Fisher Scientific). For the mRNA expression analysis, reverse transcription was performed using PrimeScript RT master mix (TaKaRa, Dalian, China). For miRNA expression analysis, total RNA was first reverse transcribed using Mir-X™ miRNA First-Strand Synthesis Kit (TaKaRa). Quantitative real-time PCR analysis was performed in triplicate on 7900 HT Real-Time PCR System (Applied Biosystems, Foster City, USA) using SYBR Premix Ex Taq (TaKaRa) and the expression levels of GAPDH or U6 was used as endogenous control. The primer sequences used for FBXW7 were as follows: forward 5′-AAAGAG TTGTTAGCGGTTCTCG-3′, reverse 5′-CCACATGGATACCAT CAAACTG-3′. Results were analyzed using the 2 -ΔΔCt calculation method.
MiRNA transfection
Mimic-miR-223 (5′-UGUCAGUUUGUCAAAUACCCCA-3′) or mimicmiR-223 NC (5′-UUCUCCGAACGUGUCACGUTT-3′) (GenePharma, Shanghai, China) were transfected into HT-29 cells at 20 nM (final concentration) using Lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions. Anti-miR-223 (5′-UGGGGUAUUU GACAAACUGACA-3′) or anti-miR-223 negative control (NC) (5′-CA GUACUUUUGUGUAGUACAA-3′) (GenePharma) were transfected into LoVo cells at 100 nM (final concentration) using Lipofectamine 3000 according to the manufacturer's instructions.
EGFP reporter assay
The cells were seeded into 48-well plates at a density of 3 × 10 4 cells/well before transfection, and when cells reached 80% confluence, the cells were co-transfected with miR-223 mimics or miR-223 inhibitor and pcDNA3/EGFP-FBXW7 3′UTR or mutant 3′UTR or control construct using Lipofectamine 3000 according to the manufacturer's instructions. The pDsRed2-N1 (Clontech, Mountain View, USA) construct was transfected with the above plasmid as the spiked-in control. The cells were harvested at 48 h after transfection and lysed with RIPA buffer, and then the fluorescence intensity was measured by the Fluorescence Spectrophotometer F-4500 (HITACHI, Tokyo, Japan).
Statistical analysis
Statistical significance between groups was determined by a twotailed Student's t-test and a one-way ANOVA test. Differences were considered to be significant when P < 0.05. Data were presented as the mean ± standard deviation (SD) and analyzed for statistical significance with GraphPad Prism 5.0 for Windows (GraphPad Software, La Jolla, USA).
Results
FBXW7 expression and doxorubicin chemosensitivity in CRC cells
In this study, we first examined the cell viabilities of four CRC cell lines including HT-29, SW480, SW620, and LoVo incubated with doxorubicin for 72 h. CCK-8 assay revealed that doxorubicin sensitivity varied among different cell lines (Fig. 1A) , and the mean doxorubicin IC 50 in HT-29, SW480, SW620, and LoVo cells were 0.34, 0.82, 1.07, and 1.46 μM, respectively (Fig. 1B) . Then, we further examined the protein and mRNA expressions of FBXW7 in the four different CRC cells. As shown in Fig. 1C ,D, the results revealed that FBXW7 expression was significantly higher in HT-29 cells compared with that in other three cells, and LoVo cells showed the lowest FBXW7 level among these four cell lines. The expression of FBXW7 had a positive relationship with doxorubicin IC 50 in four CRC cell lines.
FBXW7 is a functional target of miR-223
Several previous researches have proved that FBXW7 is a functional target of miR-223 [9, 10, 13] , and miR-223 can directly targets the FBXW7 3′UTR according to three publicly available algorithms (TargetScan, miRTarBase, and miRanda). To determine whether the 3′UTR region of FBXW7 mRNA is a direct functional target of miR-223, the EGFP reporter assay was constructed and detected in LoVo cells. The potential target sequences of miR-223 on FBXW7 mRNA's 3′UTR are shown in Fig. 2A . The results revealed that EGFP intensity was significantly decreased in cells transfected with the FBXW7 3′UTR reporter plus mimic-miR-223 compared with that in cells transfected with the mimic-NC. There was no significant decrease in cells transfected with the FBXW7 mutant 3′UTR reporter plus mimic-miR-223 and cells transfected with NC (Fig. 2B) . We then performed real-time PCR and western blot analysis to detect the effect of miR-223 on the expression of FBXW7. The results showed that miR-223 mimic significantly inhibited the expression of FBXW7, while miR-223 inhibitor increased the expression of FBXW7, compared with their respective controls (Fig. 2C,D) . These findings revealed that miR-223 has target sites in the 3′UTR of FBXW7 mRNA.
Expression of miR-223 is negatively correlated with FBXW7 expression in cells and tissues
In order to validate that miR-223 downregulated FBXW7 expression, we detected the expression level of miR-223 in different CRC cells. The results showed that miR-223 was differently expressed in four CRC cell lines, and a significant inverse correlation was observed between miR-223 and FBXW7 expression (Fig. 3A) . The result was the same when we compared the expressions of miR-223 and FBXW7 in tumor tissues and para-carcinoma tissue (Fig. 3B) . Next, we detected the expression of miR-223 and FBXW7 in early and late stage patients, it was found that the expression of miR-223 was significantly higher and FBXW7 was lower in stage III/IV patients (Fig. 3C) . Taken together, these data indicate that expression of miR-223 is negatively correlated with FBXW7 expression in cells and tissues.
Sensitivity of CRC to doxorubicin is regulated by the miR-223/FBXW7 pathway
In the first part, we have demonstrated that FBXW7 expression is associated with doxorubicin chemosensitivity in CRC cells. Next, in order to investigate whether miR-223 can regulate doxorubicin resistance through FBXW7, HT-29 and LoVo cells which have different expression of FBXW7 were selected for further study. First, miR-223 mimic or NC was transiently transfected into HT-29 cells. Downregulation of FBXW7 was observed in miR-223 overexpressing cells as compared with cells transfected with NC (Fig. 4A) . Then, the effect of miR-223 on the cell response to doxorubicin in HT-29 cells was detected by measuring the survival rate and IC 50 value. Compared with that in control cells, overexpression of miR-223 reduced the sensitivity of the cells to doxorubicin significantly (Fig. 4B) . Conversely, miR-223 inhibitor or inhibitor NC (iNC) was transiently transfected into LoVo cells. Upregulation of FBXW7 was observed in miR-223-suppressed cells as compared with cells transfected with iNC (Fig. 4C) . Compared with that in control cells, suppression of miR-223 restored the sensitivity of the cells to doxorubicin significantly (Fig. 4D) .
MiR-223 and FBXW7 regulate doxorubicin sensitivity through epithelial-mesenchymal transition
Epithelial-mesenchymal transition (EMT) has been proved to be associated with the development of chemoresistance, and doxorubicin incubation could induce EMT in several cancer cells [14, 15] . In order to confirm whether miR-223/FBXW7 pathway regulates doxorubicin sensitivity through EMT, western blot analysis, and RT-PCR were performed to determine the expression of EMTrelated markers in CRC cells. The results revealed a decreased expression of epithelial marker proteins (E-cadherin) and an increased expression of mesenchymal marker proteins (Vimentin, Twist) in HT-29 cell overexpressing miR-223 compared with cells transfected with the mimic-NC (Fig. 5A) . In contrast, after transfection of miR-223 inhibitor in LoVo cells, increased expression of epithelial marker proteins (E-cadherin) and decreased expression of mesenchymal marker proteins (Vimentin, Twist) were observed (Fig. 5B) . These results indicated that miR-223/FBXW7 axis regulates the doxorubicin sensitivity of CRC cells via affecting EMT.
Discussion
Up to now, chemotherapy has been shown to be effective in the preor post-operative treatment of CRC. Nevertheless, acquisition of drug resistance to the currently available chemotherapeutics becomes a bottleneck for successful chemotherapy [16] . Resistance to doxorubicin leads to lower response rate and higher doses of drugs, resulting in severe adverse effects [17] . Growing evidence has shown that miRNAs play important roles in the pathogenesis of malignant tumors, through the suppression of target genes involved in cancer initiation, development, metastasis, and chemo-or radio-resistance [8, 18, 19] . However, the mechanisms responsible for chemotherapy resistance mediated by miRNAs in CRC have not been clearly identified.
MiR-223 has been shown to be upregulated in many human cancers, including CRC, lung cancer, and gastric cancer [20, 21] . Specially, miR-223 was reported to be involved in chemoresistance of several chemotherapeutic reagents, such as doxorubicin, paclitaxel, trastuzumab, and cisplatin, in many cancer cells [9, 10, 22] . However, it is still unclear whether and how miR-223 regulates doxorubicin sensitivity in CRC cells. Both bioinformatics and experimentation confirmed that FBXW7 is a functional target of miR-223 in gastric cancer, esophageal squamous cell carcinoma, and non-small cell lung cancer. FBXW7 has been found to be involved in numerous cellular processes including cell differentiation, apoptosis, cell cycle, migration, and its expression change is related to tumor prognosis [23, 24] . A variety of studies have demonstrated that FBXW7 is involved in drug resistance. Inuzuka et al. [5] revealed that FBXW7 regulates the apoptotic pathway by controlling MCL1 destruction. Wertz et al. [6] reported that FBXW7 inactivation and increased Mcl-1 levels promote resistance to anti-tubulin chemotherapeutic agents and accelerate tumorigenesis. Furthermore, recent studies have reported the significant roles of miR-223/FBXW7 axis in the regulation of chemotherapeutic sensitivity of human cancers [10, 22] . In the present study, we first examined the expression of FBXW7 in four different CRC cell lines, and found that FBXW7 hi HT-29 cells displayed a higher level of chemosensitivity to doxorubicin than FBXW7 lo LoVo cells. We further confirmed that miR-223 could bind the 3′ UTR of the FBXW7 transcript using EGFR reporter assay. Moreover, FBXW7 was decreased in miR-223 mimic-transfected cells, and increased after transfection with miR-223 inhibitor, suggesting that FBXW7 is a target gene of miR-223 in CRC cells. The expression of miR-223 was negatively correlated with FBXW7 expression in cells and tissues. In the chemosensitivity experiments, we found that overexpression of miR-223 in HT-29 cell reduced both the expression of FBXW7 and the sensitivity of the cells to doxorubicin significantly. In contrast, suppression of miR-223 increased the FBXW7 expression and doxorubicin sensitivity in LoVo cells. These data suggest that miR-223 promotes the doxorubicin resistance of CRC cells by directly targeting FBXW7. It has also been well-recognized that EMT is one of the critical causes of drug resistance in cancers, and potent oncogenicity associated with EMT may be a contributory factor in inefficient drug responses and carcinoma recurrence in current systemic therapies [25, 26] . It has been suggested that reverse EMT, referred to as MET, may enable HCC cells to regain chemosensitivity [27] . In the current study, we evaluated the potential role of EMT in doxorubicin resistance associated with miR-223/FBXW7 pathway. We found that overexpression of miR-223 could induce EMT in CRC cells, as evidenced by downregulation of E-cadherin and upregulation of Vimentin.
In conclusion, our current study demonstrated that miR-223/ FBXW7 pathway plays important roles in regulation of EMT and doxorubicin sensitivity in CRC cells. Thus, this pathway potentially provides an appropriate therapeutic option for chemotherapyresistant CRC patients.
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